Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of treatment for elderly patients with acute myeloid leukemia
ChiCTR-TRC-10001209Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2010
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of homoharringtonine, cytarabine, aclarubicin and granulocyte colony-stimulating factor in acute myeloid leukemia (AML) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete remission rate in different groups. Started Sep 2010; status: completed.
02
Drugs
homoharringtoninecytarabineaclarubicingranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-TRC-10001209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001209.